Month: March 2017

ONL Therapeutics Strengthens Leadership with Addition to Board of Directors and Expansion of Operations Team Company Names New Board Member, Continues to Build Out Operations Team Through Appointment and Promotions  ANN ARBOR, MI – March 28, 2017  ONL Therapeutics, Inc., a biopharmaceutical company developing novel therapies for preserving sight in a range of retinal diseases,…

ONL Therapeutics Gets Federal Grant of $1 Million Crain’s Company also raises $1 million to fund drug for patients with retinal detachments… Read the Article

After $1M NEI Grant, ONL Therapeutics Closer to Clinical Trials Xconomy ONL Therapeutics, the Ann Arbor, MI-based biotech startup working on sight-preserving therapies for patients with retinal diseases, is one step closer to clinical trials, thanks to a cash infusion from the National Eye Institute (NEI)…. Read the Article

Ocular Surgery NewsMay 18, 2017 ONL Therapeutics closes $4.25 million in Series A funding ONL Therapeutics has closed $4.25 million in Series A funding for preclinical development of its lead therapeutic candidate, ONL1204, designed to treat retinal detachment, according to a company press release. The funding, which came from investors including Novartis, the University of…